NCT04677699View on ClinicalTrials.gov

Combined Antibody Screening for Celiac and Diabetes Evaluation

Enrolling by invitationOBSERVATIONAL
Enrollment

64,410

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

June 30, 2026

Conditions
Type 1 DiabetesCeliac Disease
Interventions
DIAGNOSTIC_TEST

Combined Risk Score

Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.

Trial Locations (1)

98122

Pacific Northwest Research Institute, Seattle

Sponsors
All Listed Sponsors
collaborator

University of Exeter

OTHER

lead

Pacific Northwest Research Institute

OTHER